Successful reduction of mother-to-child transmission of HIV-1 by nevirapine and non-breastfeeding in Hanoi and Haiphong, Vietnam

Ha, Tran Thi Thanh; Tuan, Pham Le; Bao, Nguyen Huy; Anh, Nguyễn Mai; Cam, Phung Dac; Chiodi, Francesca; Ehrnst, Anneka

doi:10.1186/1742-4690-5-s1-p11

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initially recognized, and extensively studied as a promising target for anti-cancer therapies because of its role during tumorigenesis, the PI3K/Akt cell survival pathway became a target for anti-HIV treatment after the observation that PI3K inhibitors (such as wortmannin and LY294002) or Akt inhibitors (such as miltefosine), both able to cross the BBB, contrast the cytoprotective effect exerted by Tat proteins over macrophage/microglial cells, and make them again susceptible to cell death following an apoptotic stimulus (Chugh et al, 2007, 2008). Most interestingly PI3K/Akt inhibitors proved to be effective without harming uninfected cells and therefore experimental data as far available support their possible use for HIV-therapy and targeting of long-lived viral reservoirs.…”

Section: Developing Strategiesmentioning

confidence: 99%

Challenging New Targets for CNS–HIV Infection

Ganau¹,

Prisco²,

Pescador³

et al. 2012

Front. Neur.

View full text Add to dashboard Cite

The central nervous system (CNS) represents an important target for HIV infection during multiple stages of the disease: early, after invasion of the host, acting as a viral reservoir; lately, subverting its function and causing peripheral neuropathies and neurocognitive disorders; and lastly, during the final stage of NeuroAIDS, triggering opportunistic infections, cancers, and dementia. Highly active antiretroviral therapy, a combination of drugs that inhibits enzymes essential for HIV replication, can reduce the viremia and the onset of opportunistic infections in most patients, and prolong the survival. Among the limits of the current treatments the most noticeable is the inability to eradicate HIV-infected cells, both, limiting the time frame in which antiretroviral therapies initiated after exposure to HIV can prevent infection, and allowing replication-competent virus that persists in infected cells to emerge rapidly after the cessation of treatments. Many strategies are currently under evaluation to improve HIV treatment, unfortunately more than 98% of drug candidates for CNS disorders never make it to the clinic; here in we report how nanoformulated strategies might be adapted and applied to the field of CNS–HIV infection.

show abstract

Section: Developing Strategiesmentioning

confidence: 99%